Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire backs Eisai appeal against NICE judicial review

Shire backs Eisai appeal against NICE judicial review

2nd October 2007

Shire has announced that it will act as an interested party in the appeal brought by pharmaceutical firm Eisai against the judicial review judgement regarding the decision-making process of the National Institute for Health and Clinical Excellence (NICE).

The company will back the application of Eisai to the Court of Appeal for permission to contest the High Court Ruling on the method used by NICE to come to a decision relating to the prescription of drugs to mild Alzheimer’s disease patients.

Shire notes that the revised guidance forced on NICE following the conclusion of the Judicial Review – while welcome – will only provide support on the health service for a small number of patients.

Dr Ian Howe, medical director of the company, said: “Shire is continuing as an interested party in the appeal against this judgement and the NICE Guidance, as we believe that NICE has acted unfairly.”

“NICE failed to reveal a working version of the cost-effectiveness model on which they based their decision that the drugs are not cost-effective in the early stages of the disease.”

He added that this decision means that newly-diagnosed patients with mild Alzheimer’s disease are excluded from receiving NHS support, with this procedural fairness issue now to be challenged in the High Court.

Last month, Shire criticised the NICE ruling that patients with mild Alzheimer’s Disease must in most cases be diagnosed using the Mini Mental State Examination, describing reliance on this measure as “problematic”.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.